

Bibliographie

1. Gibson, C. M. *et al.* Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. *N. Engl. J. Med.* **375**, 2423–2434 (2016).
2. Leon, M. B. *et al.* Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients. *N. Engl. J. Med.* **374**, 1609–20 (2016).
3. Køber, L. *et al.* Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure. *N. Engl. J. Med.* **375**, 1221–30 (2016).
4. Maisano, F. *et al.* Cardioband, a transcatheter surgical-like direct mitral valve annuloplasty system: early results of the feasibility trial. *Eur. Heart J.* **37**, 817–25 (2016).
5. Germain, D. P. *et al.* Treatment of Fabry's Disease with the Pharmacologic Chaperone Migalastat. *N. Engl. J. Med.* **375**, 545–55 (2016).
6. Dickinson, J. D. *et al.* IL13 activates autophagy to regulate secretion in airway epithelial cells. *Autophagy* **12**, 397–409 (2016).
7. Chu, H. *et al.* Gene-microbiota interactions contribute to the pathogenesis of inflammatory bowel disease. *Science (80-.)*. **352**, 1116–20 (2016).
8. Martinez, J. *et al.* Noncanonical autophagy inhibits the autoinflammatory, lupus-like response to dying cells. *Nature* **533**, 115–9 (2016).
9. Galluzzi, L., Pedro, J. M. B.-S., Demaria, S., Formenti, S. C. & Kroemer, G. Activating autophagy to potentiate immunogenic chemotherapy and radiation therapy. *Nat. Rev. Clin. Oncol.* (2016). doi:10.1038/nrclinonc.2016.183
10. Reck, M. *et al.* Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. *N. Engl. J. Med.* **375**, 1823–1833 (2016).
11. Michot, J. M. *et al.* Immune-related adverse events with immune checkpoint blockade: a comprehensive review. *Eur. J. Cancer* **54**, 139–48 (2016).
12. Davids, M. S. *et al.* Ipilimumab for Patients with Relapse after Allogeneic Transplantation. *N. Engl. J. Med.* **375**, 143–53 (2016).
13. Zaretsky, J. M. *et al.* Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. *N. Engl. J. Med.* **375**, 819–29 (2016).
14. Ferris, R. L. *et al.* Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. *N. Engl. J. Med.* **375**, 1856–1867 (2016).
15. Seyda Seydel, G. *et al.* Economic growth leads to increase of obesity and associated hepatocellular carcinoma in developing countries. *Ann. Hepatol.* **15**, 662–72 (2016).
16. Younossi, Z. M. *et al.* Global epidemiology of nonalcoholic fatty liver disease—Meta-analytic assessment of prevalence, incidence, and outcomes. *Hepatology* **64**, 73–84 (2016).
17. Kälsch, J. *et al.* Patients with ultrasound diagnosis of hepatic steatosis are at high metabolic risk. *Z. Gastroenterol.* **54**, 1312–1319 (2016).
18. Sanna, C., Rosso, C., Marietti, M. & Bugianesi, E. Non-Alcoholic Fatty Liver Disease and Extra-Hepatic Cancers. *Int. J. Mol. Sci.* **17**, (2016).
19. Laffer, C. L., Scott, R. C., Titze, J. M., Luft, F. C. & Eljovich, F. Hemodynamics and Salt-and-Water Balance Link Sodium Storage and Vascular Dysfunction in Salt-Sensitive Subjects. *Hypertension* **68**, 195–203 (2016).
20. Wanner, C. *et al.* Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. *N. Engl. J. Med.* **375**, 323–34 (2016).
21. Wedzicha, J. A. *et al.* Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. *N. Engl. J. Med.* **374**, 2222–34 (2016).
22. Watz, H. *et al.* Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. *Lancet. Respir. Med.* **4**, 390–8 (2016).
23. Long-Term Oxygen Treatment Trial Research Group *et al.* A Randomized Trial of Long-Term Oxygen for COPD with Moderate Desaturation. *N. Engl. J. Med.* **375**, 1617–1627 (2016).

24. Sciruba, F. C. *et al.* Effect of Endobronchial Coils vs Usual Care on Exercise Tolerance in Patients With Severe Emphysema: The RENEW Randomized Clinical Trial. *JAMA* **315**, 2178–89
25. McGeachie, M. J. *et al.* Patterns of Growth and Decline in Lung Function in Persistent Childhood Asthma. *N. Engl. J. Med.* **374**, 1842–52 (2016).
26. Peters, S. P. *et al.* Serious Asthma Events with Budesonide plus Formoterol vs. Budesonide Alone. *N. Engl. J. Med.* **375**, 850–60 (2016).
27. Stempel, D. A. *et al.* Serious Asthma Events with Fluticasone plus Salmeterol versus Fluticasone Alone. *N. Engl. J. Med.* **374**, 1822–30 (2016).
28. Stempel, D. A. *et al.* Safety of Adding Salmeterol to Fluticasone Propionate in Children with Asthma. *N. Engl. J. Med.* **375**, 840–9 (2016).
29. Du Toit, G. *et al.* Randomized trial of peanut consumption in infants at risk for peanut allergy. *N. Engl. J. Med.* **372**, 803–13 (2015).
30. Du Toit, G. *et al.* Effect of Avoidance on Peanut Allergy after Early Peanut Consumption. *N. Engl. J. Med.* **374**, 1435–43 (2016).
31. Perkin, M. R. *et al.* Randomized Trial of Introduction of Allergenic Foods in Breast-Fed Infants. *N. Engl. J. Med.* **374**, 1733–43 (2016).
32. Gomez, D. R. *et al.* Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. *Lancet. Oncol.* **17**, 1672–1682 (2016).
33. McEvoy, R. D. *et al.* CPAP for Prevention of Cardiovascular Events in Obstructive Sleep Apnea. *N. Engl. J. Med.* **375**, 919–31 (2016).
34. Zellweger, J.-P. *et al.* Risk Assessment of Tuberculosis in Contacts by IFN- γ Release Assays. A Tuberculosis Network European Trials Group Study. *Am. J. Respir. Crit. Care Med.* **191**, 1176–84 (2015).
35. Kekow, J. Biosimilars in der Rheumatologie: Eine neue Herausforderung? *Dtsch. Med. Wochenschr.* **in press**, (2017).
36. Fleischmann, R. *et al.* Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studies. *Int. J. Rheum. Dis.* (2016). doi:10.1111/1756-185X.12901
37. Dougados, M. *et al.* Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. *Ann. Rheum. Dis.* **76**, 88–95 (2017).
38. Ramiro, S. *et al.* Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis. *Ann. Rheum. Dis.* **75**, 490–8 (2016).
39. Nissen, S. E. *et al.* Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. *N. Engl. J. Med.* **375**, 2519–29 (2016).